Parabilis Medicines Inc (PBLS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$24.44-9.21%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Parabilis Medicines Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	750,000
EPS	—	-0.376
Annual ending 2026-12-31
Revenue	—	1.19M
EPS	—	-3.09
Annual ending 2027-12-31
Revenue	—	4.75M
EPS	—	-2

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance zolucatetide clinical development across multiple indications	Parabilis Medicines is advancing its lead drug, zolucatetide, across multiple cancer indications.	Intact	failure to progress in clinical trials or regulatory submissions	Qualitative progress confirmed (Phase 1/2 data + new FAP study) Phase 1/2 desmoid data reported; FAP dose-ranging study initiated; CMO transition noted but no trial failures. Context reviewed through Oct 24, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management emphasized advancing zolucatetide clinical development across multiple indications in the August 2026 disclosure. Financials show minimal revenue of $148K and operating loss of $50.9M in 2026-Q2, consistent with clinical-stage status. The trajectory is early-stage with limited revenue but ongoing clinical focus. Delivery assessment Oct 24, 2026
Strengthen leadership with experienced oncology drug developer	A supporting condition in Parabilis Medicines Inc's published investment case. The stated target is qualitative.	Intact	leadership changes that do not align with strategic goals	Qualitative: Leadership aligned with strategic goals News confirms Craig Tendler, a former J&J oncology executive, joined the board on 2026-08-25, aligning with strategic goals. Context reviewed through Oct 24, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management announced the appointment of Dr. Tendler to the Board to strengthen leadership in oncology drug development. Financials show ongoing operating losses consistent with clinical-stage biopharma. This leadership addition aligns with the strategic focus on clinical and regulatory advancement. Delivery assessment Oct 24, 2026
Expand Helicon-based pipeline beyond zolucatetide	A supporting condition in Parabilis Medicines Inc's published investment case. The stated target is qualitative.	Intact	inability to develop new therapeutics or secure funding	Qualitative: 2 new indications (desmoid, FAP) advanced Phase 1/2 data reported for desmoid tumors; dose-ranging study initiated for FAP; Regeneron investment secured. Context reviewed through Oct 24, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management disclosed expansion of the Helicon therapeutic pipeline beyond zolucatetide. Financials show the company remains in early clinical development with $148K revenue and $50.9M operating loss in 2026-Q2. The trajectory is consistent with early-stage pipeline expansion. Delivery assessment Oct 24, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	2 / 3
2026-09-27	Unavailable	Unavailable	2 / 3
2026-09-28	Unavailable	Unavailable	2 / 3
2026-09-29	Unavailable	Unavailable	2 / 3
2026-09-30	Unavailable	Unavailable	2 / 3
2026-10-01	Unavailable	Unavailable	2 / 3
2026-10-02	Unavailable	Unavailable	2 / 3
2026-10-03	Unavailable	Unavailable	2 / 3
2026-10-04	Unavailable	Unavailable	2 / 3
2026-10-05	Unavailable	Unavailable	2 / 3
2026-10-06	Unavailable	Unavailable	2 / 3
2026-10-07	Unavailable	Unavailable	2 / 3
2026-10-08	Unavailable	Unavailable	2 / 3
2026-10-09	Unavailable	Unavailable	2 / 3
2026-10-10	Unavailable	Unavailable	2 / 3
2026-10-11	Unavailable	Unavailable	2 / 3
2026-10-12	Unavailable	Unavailable	2 / 3
2026-10-13	Unavailable	Unavailable	2 / 3
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	2 / 3
2026-10-17	Unavailable	Unavailable	2 / 3
2026-10-18	Unavailable	Unavailable	2 / 3
2026-10-19	Unavailable	Unavailable	2 / 3
2026-10-20	Unavailable	Unavailable	2 / 3
2026-10-21	Unavailable	Unavailable	2 / 3
2026-10-22	Unavailable	Unavailable	2 / 3
2026-10-23	Unavailable	Unavailable	2 / 3
2026-10-24	Unavailable	Unavailable	2 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 22

$40.00New observation · no comparable prior

$0$22.00$44.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Review the published break conditions above; missing evidence is not proof of success.

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

The available assessments flag no unresolved thesis condition. The next results still need to support the ongoing thesis conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-45.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Parabilis Medicines Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The long-term thesis remains insufficiently clear because the available financial history is limited, and confidence in the overall evidence is low.

What's priced into Parabilis Medicines Inc

The evidence does not provide a valuation measure or a clear account of what market expectations already assume, so whether PBLS is cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that alone does not establish that expectations are modest.

What the fundamentals likely do

In the near term, the company is likely to remain focused on clinical development and pipeline expansion, with minimal revenue and substantial operating losses reported in 2026-Q2. Recent earnings misses and an elevated next-quarter miss risk add uncertainty; management priorities and leadership changes are consistent with an early clinical-stage business, but their outcomes are not yet established.

What Parabilis Medicines Inc hinges on

Over the multi-year view, the thesis hinges on progress advancing zolucatetide across indications and building the Helicon pipeline beyond it. Near-term sector signals are mixed: strong results and guidance from healthcare bellwethers could support the sector backdrop, while weaker employment data or bellwether misses could weaken it.